Weight Loss Clinic in Faridabad | Dr Vishal khurana
Safe, medical weight loss in Faridabad with GLP-1, gastric balloon, diet & gut-liver evaluation by board-certified gastroenterologist Dr Vishal Khurana.
Struggling with weight?
Get safe, medical weight loss in Faridabad, Gurugram, Palwal, Noida, Delhi NCR with diet, lifestyle and gut-liver evaluation by a gastro-liver specialist.
Weight Loss in Delhi NCR – Medical, Safe & Sustainable
Uncontrolled weight gain is not just a cosmetic issue; it is strongly linked to fatty liver, diabetes, high cholesterol, PCOS, sleep apnea and heart disease. At the clinic in Faridabad, weight loss is approached as a medical condition, combining gut and liver evaluation, customised nutrition, activity planning and evidence-based therapies rather than crash diets or gimmicks
FAQs on Weight Loss
Q1. Which doctor is best for weight loss in Faridabad?
Patients who have weight gain with fatty liver, diabetes, high cholesterol, PCOS or digestive problems often benefit from seeing a gastroenterologist and liver specialist for medical weight management in Faridabad, as both obesity and underlying gut–liver conditions are treated together.
Q2. Is weight loss treatment in Faridabad safe?
When supervised by a qualified specialist, weight loss plans are built around clinical assessment, lab reports and comorbidities, avoiding crash diets, unregulated supplements and unsafe injections, which makes the process medically safe and sustainable.
Q3. How long does healthy weight loss take?
Most people are guided towards a realistic target of 0.5–1 kg per week, with the focus on inch loss, metabolic improvement and maintenance rather than just the number on the scale.
Q4. Can I reverse fatty liver with weight loss?
Losing 7–10% of body weight can significantly reduce liver fat and inflammation in non-alcoholic fatty liver disease, especially when combined with the right diet and activity pattern.
Q5. How do I book a consultation for weight loss in Faridabad?
You can book an appointment by calling the clinic, using the online booking form on this website or through major healthcare platforms that list weight loss and gastro-liver services in Faridabad.
Q6. What are GLP‑1 weight loss medications?
GLP‑1 receptor agonists are injectable or oral medicines that mimic a natural gut hormone (glucagon‑like peptide‑1) to reduce appetite, slow stomach emptying and improve blood sugar. They were first used for type 2 diabetes and are now approved in higher doses for medical weight loss in people with obesity or overweight with risk factors.
Q7. Which GLP‑1 and “new” weight loss drugs are commonly used?
Common GLP‑1 medicines include liraglutide, semaglutide and dulaglutide, while newer incretin‑based drugs like tirzepatide act on both GLP‑1 and GIP receptors. Among these, semaglutide and tirzepatide show the greatest average weight loss in clinical studies.
Q8. How much weight loss can these medicines achieve?
On average, older GLP‑1 drugs like liraglutide lead to around 5% more weight loss than placebo, semaglutide around 10–12%, and tirzepatide 15–20% or more with continued use. Many patients achieve at least 5–10% body‑weight reduction within 6–12 months when medication is combined with diet and lifestyle changes.
Q9. Who is a good candidate for a GLP‑1 or similar weight loss injection?
These drugs are usually considered for adults with BMI ≥30, or BMI ≥27 with obesity‑related problems such as diabetes, fatty liver disease, high blood pressure or sleep apnea. Careful medical assessment is needed to rule out contraindications and to decide whether tablets, injections or other options are safer.
Q10. How do GLP‑1 drugs actually work in the body?
They increase insulin release when blood sugar rises, reduce glucagon, slow gastric emptying and act on brain centres that control hunger, which together help you feel full with smaller portions. This dual effect on glucose and appetite makes them useful for both diabetes control and weight reduction.
Q11. What are the common side effects?
Most side effects are gastrointestinal and include nausea, vomiting, diarrhoea, constipation, abdominal pain, bloating or early fullness, especially when doses are increased too quickly. These are usually mild to moderate and often improve over time or with dose adjustment and dietary changes.
Q12. Are there any serious or long‑term risks?
Rare but important risks include gallbladder or biliary disease, pancreatitis, bowel obstruction and significant delayed gastric emptying, which may affect procedures like anaesthesia or endoscopy. Possible links with thyroid tumours and nutritional deficiencies are being investigated, so long‑term users need monitoring and regular follow‑up.
Q13. Do I have to stay on GLP‑1 injections forever?
Weight regain is common if medication is stopped and lifestyle changes are not maintained, because appetite and metabolism tend to drift back towards baseline. The goal is to use the drug alongside diet, activity and behaviour change so that, if the dose is reduced later, as much of the weight loss as possible can be preserved.
Q14. How are these medicines started and monitored?
Treatment usually starts with a low weekly or daily dose and is slowly escalated to reduce side effects, with periodic checks of weight, waist, blood sugar, kidney function and other labs. Dose changes, pauses before surgery, and management of side effects should always be guided by a qualified clinician familiar with GLP‑1 therapies.
Q15. Can GLP‑1 drugs replace diet and exercise?
No; they work best when combined with a structured nutrition plan, adequate protein, physical activity, sleep regulation and counselling on eating behaviour. Using injections alone without lifestyle support increases the risk of side effects, nutritional deficiencies and rapid weight regain when the drug is stopped.
Q16. Are GLP‑1 and new drugs safe for everyone with obesity?
They are not recommended for certain patients, such as those with a history of specific thyroid cancers, severe pancreatitis, advanced kidney disease or some gastrointestinal motility disorders. Individual benefit–risk assessment is essential, particularly in older adults, people on multiple medicines or those planning surgery.
Q17. How do newer drugs like tirzepatide compare with older GLP‑1s?
Real‑world and trial data suggest tirzepatide leads to greater average weight loss and higher proportions of patients achieving 10–15% or more weight reduction than semaglutide in many cohorts.